Paxlovid (Nirmatrelvir 150mg & Ritonavir 100mg Tablets)
Description:
Paxlovid is an oral antiviral medication comprising two active components: Nirmatrelvir and Ritonavir. It is used for the treatment of mild to moderate COVID-19 in patients at high risk of progressing to severe disease.
Nirmatrelvir (PF-07321332) is a SARS-CoV-2 main protease (Mpro) inhibitor, also known as a 3CL protease inhibitor. It acts by blocking the activity of the viral protease enzyme, which is essential for the replication of the coronavirus. By inhibiting this enzyme, nirmatrelvir disrupts viral multiplication, particularly in the early stages of infection.
Ritonavir, a protease inhibitor used here in a low dose, functions as a pharmacokinetic enhancer. It increases the plasma concentration of nirmatrelvir by slowing its breakdown, thereby enhancing its antiviral effect.
Therapeutic Use:
Treatment of mild to moderate COVID-19 in adults and pediatric patients (age ≥12 years and weighing ≥40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death.
Mechanism of Action:
The combination targets viral replication at an early stage. Nirmatrelvir blocks the protease enzyme required for viral protein processing, while Ritonavir boosts its effectiveness by inhibiting its metabolism.
Packaging:
Typically supplied as a blister pack containing both nirmatrelvir and ritonavir tablets, formulated for a 5-day treatment course.
Note:
Paxlovid should be administered as soon as possible after diagnosis of COVID-19 and within five days of symptom onset. Use only under the supervision of a healthcare professional. It is not a substitute for vaccination.
Would you like this adapted for export listings or regulatory submission?
